Advertisement
ABBV vs BMY
Which Stock Would AI Choose? AbbVie (ABBV) vs. Bristol-Myers Squibb (BMY) Stock Comparison
Key Takeaways
- AbbVie (ABBV) has delivered stronger one-year total shareholder returns of approximately 40% compared to more modest gains for Bristol-Myers Squibb (BMY).
- Both companies are preparing to report second-quarter 2026 earnings in late July, with analysts expecting EPS growth for each.
- AbbVie (ABBV) benefits from a diversified immunology portfolio including Skyrizi, while facing a recent setback in its epcoritamab trial.
- Bristol-Myers Squibb (BMY) maintains a broad oncology and cardiovascular focus, with recent FDA approvals supporting its pipeline.
- Year-to-date performance shows Bristol-Myers Squibb (BMY) slightly ahead at around 19%, versus AbbVie (ABBV) at approximately 16%.
- Analyst consensus remains favorable for both, with AbbVie (ABBV) carrying a higher average price target relative to current levels.
Introduction
This comparison examines AbbVie (ABBV) and Bristol-Myers Squibb (BMY), two leading pharmaceutical companies with substantial market capitalizations and established product portfolios. The analysis focuses on recent stock behavior, business fundamentals, and market positioning within the healthcare sector. Traders and investors seeking to evaluate relative performance between established biopharmaceutical names in a period of upcoming earnings reports may find this overview relevant for assessing sector exposure and momentum differences.
AbbVie Overview and Recent Performance
AbbVie (ABBV) is a research-based biopharmaceutical company known for its immunology, oncology, and neuroscience portfolios, with key products including Skyrizi and Rinvoq. In recent weeks, the stock has traded near its 52-week high of approximately $261.64, closing at $259.36 on July 24, 2026. Performance reflects resilience amid a mixed backdrop, including a setback in the epcoritamab trial that introduced some growth concerns. Broader market activity shows year-to-date gains near 16% and one-year returns around 40%, outpacing broader indices. Sentiment has been supported by analyst buy ratings and expectations for 23.2% EPS growth in the upcoming quarterly report scheduled for July 31, 2026.
Bristol-Myers Squibb Overview and Recent Performance
Bristol-Myers Squibb (BMY) operates as a global biopharmaceutical company with strengths in oncology, hematology, immunology, and cardiovascular disease. Recent market activity places the stock around $62.09 as of July 24, 2026, within a 52-week range of $42.52 to $62.89. The shares have posted year-to-date advances near 19%, with earnings scheduled for July 30, 2026, where analysts project EPS of $1.59. Recent developments include FDA approvals that bolster the product lineup. Performance in recent weeks has been influenced by pipeline updates and overall sector rotation, with the stock maintaining stability ahead of the earnings release.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from a library of hundreds that cover thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in this section. Available bots span diverse trading styles, strategies, timeframes, and performance statistics, with metrics such as win rates, profit factors, and drawdowns varying widely across the platform. This variety allows users to explore options suited to different risk tolerances and market views. Review the Trending AI Robots page for current selections and detailed bot profiles.
Head-to-Head Comparison
AbbVie (ABBV) and Bristol-Myers Squibb (BMY) both operate in the pharmaceutical sector but differ in growth drivers and risk profiles. AbbVie (ABBV) emphasizes immunology expansion through newer assets like Skyrizi, supporting higher historical returns, while navigating patent cliffs and trial outcomes. Bristol-Myers Squibb (BMY) relies on a broader oncology and cardiovascular pipeline, with recent approvals providing catalysts amid steadier but lower-magnitude price appreciation. Momentum favors AbbVie (ABBV) on longer-term metrics, whereas Bristol-Myers Squibb (BMY) shows relative outperformance year-to-date. Both face sector risks including regulatory shifts and competition, with market sentiment reflecting cautious optimism ahead of earnings. Trade-offs center on AbbVie (ABBV)’s premium valuation versus Bristol-Myers Squibb (BMY)’s potentially wider pipeline diversification.
Tickeron AI Verdict
Based on observable factors including trend consistency, relative returns, and positioning ahead of earnings, Tickeron’s AI models would currently assign a modestly higher probability of favorable near-term momentum to AbbVie (ABBV). Stronger one-year performance and analyst-supported growth expectations contribute to this assessment, though outcomes remain subject to earnings results and broader market conditions for both names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and BMY is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 3 FA rating(s) are green whileBMY’s FA Score has 3 green FA rating(s).
- ABBV’s FA Score: 3 green, 2 red.
- BMY’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while BMY’s TA Score has 3 bullish TA indicator(s).
- ABBV’s TA Score: 4 bullish, 3 bearish.
- BMY’s TA Score: 3 bullish, 4 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +1.04% price change this week, while BMY (@Pharmaceuticals: Major) price change was +0.11% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.32%. For the same industry, the average monthly price growth was +2.73%, and the average quarterly price growth was +2.90%.
Reported Earning Dates
ABBV is expected to report earnings on Oct 23, 2026.
BMY is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+2.32% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | BMY | ABBV / BMY | |
| Capitalization | 440B | 130B | 338% |
| EBITDA | 16.9B | 16.8B | 101% |
| Gain YTD | 11.445 | 22.085 | 52% |
| P/E Ratio | 70.27 | 14.03 | 501% |
| Revenue | 62.8B | 49.2B | 128% |
| Total Cash | N/A | 11.1B | - |
| Total Debt | 72.9B | 45.1B | 162% |
ABBV | BMY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 76 | 44 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 41 Fair valued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 7 | 83 | |
SMR RATING 1..100 | 1 | 22 | |
PRICE GROWTH RATING 1..100 | 28 | 21 | |
P/E GROWTH RATING 1..100 | 80 | 79 | |
SEASONALITY SCORE 1..100 | 47 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (3) in the Pharmaceuticals Major industry is somewhat better than the same rating for ABBV (41). This means that BMY’s stock grew somewhat faster than ABBV’s over the last 12 months.
ABBV's Profit vs Risk Rating (7) in the Pharmaceuticals Major industry is significantly better than the same rating for BMY (83). This means that ABBV’s stock grew significantly faster than BMY’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as BMY (22). This means that ABBV’s stock grew similarly to BMY’s over the last 12 months.
BMY's Price Growth Rating (21) in the Pharmaceuticals Major industry is in the same range as ABBV (28). This means that BMY’s stock grew similarly to ABBV’s over the last 12 months.
BMY's P/E Growth Rating (79) in the Pharmaceuticals Major industry is in the same range as ABBV (80). This means that BMY’s stock grew similarly to ABBV’s over the last 12 months.
| ABBV | BMY | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 36% |
| Stochastic ODDS (%) | 2 days ago 65% | 2 days ago 59% |
| Momentum ODDS (%) | 2 days ago 40% | 2 days ago 57% |
| MACD ODDS (%) | 2 days ago 42% | 2 days ago 53% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 55% |
| TrendMonth ODDS (%) | 2 days ago 65% | 2 days ago 58% |
| Advances ODDS (%) | 3 days ago 60% | 7 days ago 55% |
| Declines ODDS (%) | 10 days ago 48% | N/A |
| BollingerBands ODDS (%) | 2 days ago 64% | 2 days ago 61% |
| Aroon ODDS (%) | 2 days ago 62% | 2 days ago 67% |
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -0.53% | ||
| NVS - ABBV | 52% Loosely correlated | -1.48% | ||
| BMY - ABBV | 50% Loosely correlated | +0.14% | ||
| JNJ - ABBV | 47% Loosely correlated | +0.41% | ||
| MRK - ABBV | 46% Loosely correlated | +1.92% | ||
| AMGN - ABBV | 46% Loosely correlated | +0.45% | ||
More | ||||
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with AMGN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | +0.14% | ||
| AMGN - BMY | 57% Loosely correlated | +0.45% | ||
| PFE - BMY | 57% Loosely correlated | -1.16% | ||
| NVS - BMY | 55% Loosely correlated | -1.48% | ||
| GSK - BMY | 53% Loosely correlated | -1.18% | ||
| ABBV - BMY | 49% Loosely correlated | -0.53% | ||
More | ||||